Y-mAbs to Present Preclinical GD2-SADA Data at 2024 SNMMI Meeting
Y-mAbs Therapeutics (Nasdaq: YMAB), a biopharmaceutical company specializing in innovative radioimmunotherapy and antibody-based treatments for cancer, has revealed plans to showcase preclinical data on GD2-SADA at the Society of Nuclear Medicine & Molecular Imaging (SNMMI) 2024 Annual Meeting, set for June 8 – 11, 2024, in Toronto, Canada.
High-Affinity Binding Properties of GD2-SADA
The poster, titled “High-affinity and specific binding between DOTA-chelated lanthanides and GD2-SADA, a self-assembling and disassembling bispecific fusion protein for pre-targeted” (poster #241436), explores the binding characteristics of the GD2-SADA fusion protein. GD2-SADA is a Self-Assembling and DisAssembling (SADA) bispecific fusion protein designed for a two-step pre-targeted radioimmunotherapy (PRIT) approach. This study highlights real-time, high-affinity interactions between GD2-SADA and various "caged" lanthanide metals, which are significant for both diagnostic and therapeutic purposes.
Johannes Nagel, Ph.D., lead author of the study, emphasized the potential clinical applications of GD2-SADA for diagnosing and treating GD2-expressing tumors. "The results bolster the potential clinical utility of GD2-SADA and our ability to advance our radiochemistry program," stated Dr. Nagel. He also mentioned that the strong preclinical data supports the ongoing Phase 1 clinical development of GD2-SADA.
Development and Licensing of SADA Technology
The SADA technology for radioimmunotherapy was developed by researchers at Memorial Sloan Kettering Cancer Center (MSK), led by Dr. Nai-Kong V. Cheung, M.D., Ph.D. This technology has been exclusively licensed to Y-mAbs by MSK. Dr. Cheung holds intellectual property rights in the technology, and MSK has financial interests in both the technology and Y-mAbs due to this licensing agreement.
About Y-mAbs
Y-mAbs Therapeutics Inc. is a commercial-stage biopharmaceutical company focused on creating and marketing novel therapies for cancer. Their technological arsenal includes the investigational SADA Pretargeted Radioimmunotherapy Platform (PRIT) and bispecific antibodies created with the Y-BiClone platform. The company’s diverse and advanced product lineup features the anti-GD2 therapy DANYELZA® (naxitamab-gqgk), which is the first FDA-approved treatment for patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow following various levels of response to prior therapy.
About GD2-SADA PRIT
GD2-SADA is a bispecific fusion protein that shows strong binding to the glycolipid GD2 and Lutetium 177 (Lu 177)-DOTA, a chelated radionuclide. The two-step PRIT process involves an initial infusion of non-radiolabeled GD2-SADA tetramers, which bind to GD2-expressing tumors. Any unbound GD2-SADA disassembles into monomers, which are then excreted by the kidneys. The second step involves administering the radioactive payload, which targets the GD2-SADA bound to tumor cells, delivering localized radiation. This GD2-SADA PRIT method with Lutetium 177-DOTA is currently under investigation in both adults and adolescents in Trial 1001 (NCT05130255).
How to obtain the latest research advancements in the field of biopharmaceuticals?
In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!
